Oragenics, Inc. (NYSEAMERICAN:OGEN) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totalling 163,247 shares, a growth of 41.5% from the April 13th total of 115,364 shares. Currently, 6.4% of the shares of the stock are short sold. Based on an average trading volume of 213,284 shares, the days-to-cover ratio is presently 0.8 days.
Oragenics opened at $1.30 on Friday, MarketBeat Ratings reports. Oragenics has a one year low of $1.30 and a one year high of $1.34.
Oragenics, Inc focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.